Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report

Cakmak M. E. , KAYA S. B. , CAN BOSTAN Ö. , TUNCAY G. , DAMADOĞLU E. , KARAKAYA G. , ...Daha Fazla

ASTIM ALLERJI IMMUNOLOJI, cilt.18, ss.27-29, 2020 (ESCI İndekslerine Giren Dergi) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18
  • Basım Tarihi: 2020
  • Doi Numarası: 10.21911/aai.584
  • Sayfa Sayıları: ss.27-29


Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world. SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases. There are concerns that COVID-19 will be more severe in patients with severe asthma. The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown. In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19. To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma.